India's Drug-Industry Woes No Deterrence To More Than Doubled Market
This article was originally published in PharmAsia News
Executive Summary
Despite its U.S. FDA, regulatory and other problems, India's pharmaceutical market is expected to more than double its value over the next seven years, from $21 billion to $56 billion.
You may also be interested in...
US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Execs On The Move: New CFOs At Pacific Biosciences, Aziyo Biologics; Illumina Gets Marketing Boss
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: